Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Assets: 2022-2025

Historic Assets for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $11.5 million.

  • bioAffinity Technologies' Assets rose 76.23% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 76.23%. This contributed to the annual value of $6.5 million for FY2024, which is 20.77% down from last year.
  • Latest data reveals that bioAffinity Technologies reported Assets of $11.5 million as of Q3 2025, which was up 143.03% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Assets ranged from a high of $14.1 million in Q3 2022 and a low of $4.8 million during Q2 2025.
  • In the last 3 years, bioAffinity Technologies' Assets had a median value of $8.0 million in 2024 and averaged $7.9 million.
  • As far as peak fluctuations go, bioAffinity Technologies' Assets tumbled by 35.70% in 2024, and later spiked by 76.23% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Assets (Quarterly) stood at $12.2 million in 2022, then slumped by 32.51% to $8.2 million in 2023, then fell by 20.77% to $6.5 million in 2024, then spiked by 76.23% to $11.5 million in 2025.
  • Its last three reported values are $11.5 million in Q3 2025, $4.8 million for Q2 2025, and $5.5 million during Q1 2025.